Ryvu Therapeutics SA (RVU) — Working Capital to Net Assets Ratio
Ryvu Therapeutics SA (RVU) has a Working Capital to Net Assets ratio of 144.3% as of December 2025. Working capital of zł77.67 Million (current assets of zł139.25 Million minus current liabilities of zł61.58 Million) is measured against net assets of zł53.83 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See RVU equity financing ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Ryvu Therapeutics SA Working Capital to Net Assets (2010–2025)
This chart shows how Ryvu Therapeutics SA's Working Capital to Net Assets ratio has evolved across 16 annual periods from 2010 to 2025. As of December 2025, the ratio stands at 144.3%, reflecting working capital of zł77.67 Million against net assets of zł53.83 Million PLN. Check tangible equity quality of Ryvu Therapeutics SA to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Ryvu Therapeutics SA (2010–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Ryvu Therapeutics SA from 2010 to 2025, covering 16 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see RVU stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (PLN) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 144.3% | zł77.67 Million | zł53.83 Million | zł139.25 Million | zł61.58 Million | ▲ +29.9 pp |
| 2024 | 114.3% | zł164.51 Million | zł143.88 Million | zł272.44 Million | zł107.93 Million | ▲ +33.9 pp |
| 2023 | 80.4% | zł208.69 Million | zł259.59 Million | zł278.39 Million | zł69.70 Million | ▼ -13.7 pp |
| 2022 | 94.1% | zł323.12 Million | zł343.39 Million | zł367.93 Million | zł44.81 Million | ▲ +53.9 pp |
| 2021 | 40.2% | zł68.05 Million | zł169.42 Million | zł104.25 Million | zł36.20 Million | ▼ -21.8 pp |
| 2020 | 61.9% | zł138.55 Million | zł223.72 Million | zł172.36 Million | zł33.81 Million | ▲ +12.3 pp |
| 2019 | 49.6% | zł59.38 Million | zł119.76 Million | zł89.98 Million | zł30.60 Million | ▼ -21.1 pp |
| 2018 | 70.6% | zł137.65 Million | zł194.86 Million | zł173.22 Million | zł35.57 Million | ▲ +18.9 pp |
| 2017 | 51.8% | zł33.12 Million | zł64.00 Million | zł59.87 Million | zł26.75 Million | ▲ +0.2 pp |
| 2016 | 51.6% | zł28.74 Million | zł55.71 Million | zł47.67 Million | zł18.93 Million | ▼ -17.1 pp |
| 2015 | 68.7% | zł32.20 Million | zł46.88 Million | zł48.52 Million | zł16.32 Million | ▲ +46.7 pp |
| 2014 | 22.0% | zł2.04 Million | zł9.25 Million | zł17.31 Million | zł15.27 Million | ▲ +27.5 pp |
| 2013 | -5.4% | zł-170.44K | zł3.13 Million | zł11.19 Million | zł11.36 Million | ▼ -18.4 pp |
| 2012 | 12.9% | zł716.24K | zł5.53 Million | zł8.09 Million | zł7.38 Million | ▼ -41.1 pp |
| 2011 | 54.0% | zł6.19 Million | zł11.46 Million | zł10.10 Million | zł3.90 Million | ▲ +317.8 pp |
| 2010 | -263.7% | zł-3.96 Million | zł1.50 Million | zł2.55 Million | zł6.51 Million | — |